Skip to main content

Table 3 Univariate and multivariable Cox regression analysis of clinical and imaging predictors for MACE in the training cohort

From: CT-derived fractional flow reserve for prediction of major adverse cardiovascular events in diabetic patients

 

Univariate analysis

Multivariate analysis 1*

Multivariate analysis 2*

HR

95%CI

p value

HR

95%CI

p value

HR

95%CI

p value

Age (per + 1 year)

1.034

1.010–1.059

0.006

1.016

0.991–1.042

0.214

1.020

0.994–1.048

0.131

Male

1.520

0.909–2.541

0.110

      

BMI, (per + 1 kg/m2)

0.994

0.926–1.066

0.859

      

Course of Diabetes (per + 1 year)

1.018

0.990–1.047

0.202

      

Hypertension

1.682

1.000–2.829

0.050

1.202

0.700–2.063

0.504

1.078

0.621–1.869

0.790

Dyslipidemia

0.991

0.607–1.616

0.970

      

Current smoking

1.042

0.623–1.744

0.875

      

fast glucose (per + 1 mmol/L)

1.037

0.983–1.094

0.186

      

HbA1c (per + 1%)

1.127

1.015–1.252

0.025

1.133

1.017–1.263

0.024

1.142

1.026–1.272

0.015

CACS (per + 1)

1.002

1.001–1.002

 < 0.001

1.001

1.001–1.002

 < 0.001

1.001

1.000–1.001

0.089

CT-FFR ≤ 0.8

10.865

6.627–17.814

 < 0.001

   

4.534

2.468–8.330

 < 0.001

CAD-RADS ≥ 3

6.109

3.579–10.429

 < 0.001

2.192

1.117–4.299

0.022

1.856

0.932–3.697

0.078

Any HRP

4.530

2.737–7.499

 < 0.001

0.567

0.146–2.206

0.413

0.375

0.090–1.564

0.178

Any LAP

5.075

3.035–8.485

 < 0.001

3.667

1.031–13.048

0.045

3.973

1.060–14.893

0.041

Any PR

5.138

2.619–10.079

 < 0.001

1.571

0.624–3.954

0.338

1.661

0.652–4.231

0.288

Any SC

2.667

1.319–5.395

0.006

1.046

0.492–2.225

0.908

0.907

0.419–1.961

0.804

Any NRS

3.104

1.739–5.540

 < 0.001

1.311

0.681–2.524

0.418

1.209

0.624–2.344

0.573

Microvascular complications

1.250

0.710–2.200

0.439

      

Insulin secretagogues

0.638

0.353–1.152

0.136

      

TZDs

1.698

0.415–6.941

0.461

      

Insulin

0.887

0.540–1.456

0.634

      

Biguanides

0.925

0.568–1.507

0.755

      

α-Glucosidase inhibitors

1.718

1.053–2.805

0.030

1.516

0.915–2.512

0.107

1.626

0.975–2.713

0.063

DPP-4 inhibitors

1.498

0.895–2.507

0.124

      

SGLT-2 inhibitor

1.623

0.508–5.192

0.414

      

GLP-1 RAs

1.402

0.439–4.474

0.568

      

β-blockers

1.143

0.416–3.145

0.795

      

ACEI

1.344

0.580–3.112

0.491

      

ARB

1.106

0.648–1.888

0.712

      

Ca2 + channel blockers

0.986

0.578–1.682

0.958

      

Statins

1.678

0.896–3.141

0.106

      
  1. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor antagonist; BMI, body mass index; CACS, Coronary Artery Calcium Scoring; CAD-RADS, Coronary Artery Disease—Reporting and Data System; CT-FFR, computed tomography fractional flow reserve; DPP-4, dipeptidyl peptidase 4; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HbA1c, hemoglobin A1c; HRP, high-risk plaque; LAP, low-attenuation plaque; MACE, major adverse cardiovascular event; NRS, napkin-ring sign; PR, positive remodeling; SC, spotty calcification; SGLT-2, sodium-glucose cotransporter 2; TZDs, Thiazolidinedione drugs
  2. *Multivariate analysis 1 was used for constructing model 1 and multivariate analysis 2 was used for constructing model 2
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840